Abstract:Objective To investigate the safety and clinical efficacy of microparticle transcatheter arterial chemoembolization (mTACE) combined with surgical resection for the treatment of huge hepatocellular carcinoma (hHCC; ≥ 10 cm). Methods A retrospective descriptive study was conducted to gather the clinical data of nine patients with hHCCs treated with mTACE combined with resection in Beijing Tsinghua Changgung Hospital from December 2016 to July 2020. The outcome were as follows: (1) the excellent effect and adverse reactions of mTACE and (2) the efficacy and safety of perioperative resection. Count data were expressed as absolute numbers and percentages. The measurement data of the normal distribution is represented by X ± S, and the measurement data of the skewed distribution are represented by M (range). A paired t-test was used to compare the data of the same patient. p values <0.05 are considered statistically significant. Results (1) Regarding the efficacy and safety of mTACE, all nine hHCCs were treated with mTACE one time. The tumor necrosis rate after particle TACE was (77.6 ± 15.7)% (51.7%–100%); according to the modified response evaluation criteria in solid tumors, the objective response was partial response in eight patients and complete response in one patient. The alpha fetoprotein (AFP) level was abnormal in six cases (>20 ng/mL), of which three cases exceeded the maximum value (>30,000 ng/mL) pre-mTACE. In six patients with abnormal AFP levels, the AFP level decreased in five patients, with a median percentage of 74.5% (35.2%–96.0%). The PIVKA-II level in nine patients was > 40 mAU/mL before mTACE and decreased to varying degrees after mTACE. The median percentage of decline was 76.0% (4.5%–99.8%). The maximum diameter of the tumor decreased from (13.9 ± 1.9) cm (11.0–16.4 cm) to (12.8 ± 1.9) cm (10.4–15.6 cm) (P = 0.001) before surgical resection. Prior to the surgical resection, the tumor volume decreased from (897 ± 244) mL (436–1250 mL) to (750 ± 291) mL (260–1130 mL) (P = 0.001), and the residual liver volume/standard liver volume increased from (42.8 ± 12.8)% (25.8%–61.3%) to (50.2 ± 14.9)% (28.8%–67.4%) (P = 0.008). All patients had embolism syndrome such as fever and abdominal pain in varying degrees, and no serious complications such as liver abscess, liver and kidney failure, or ectopic embolism were noted. (2) For perioperative efficacy and safety, all lesions were successfully resected in (31 ± 11) days (14–48 days) after mTACE. The operation time was (395 ± 79) min (296–540 min), and the amount of intraoperative bleeding was (433 ± 158) mL (200–600 mL). Complications such as biliary fistula, abdominal bleeding, liver and kidney failure, or abdominal infection were not found. The postoperative hospital stay was (13 ± 4) days (9–19 days). No tumor invasion was found at the cutting edge, and hepatic vein invasion was observed in one case. (3) The follow-up ended in November 2021, with a median follow-up of 34 months (16–46 months). Recurrence or distant metastasis occurred in four patients, of which two patients died. The survival times were 18 and 31 months, respectively. The other two patients were followed up for 34 and 41 months. The remaining five patients were followed up for 16–46 months without antitumor treatment or disease progression. Conclusions mTACE combined with tumor resection is feasible for the treatment of patients with hHCC, which needs to be further confirmed by prospective studies.

Multiple hepatocellular carcinomas: liver resection or transcatheter arterial chemoembolization?

Surgical Resection Plus Radiofrequency Ablation for the Treatment of Multifocal Hepatocellular Carcinoma.

Surgical Resection Plus Radiofrequency Ablation Versus Radical Surgery for Hepatocellular Carcinoma: A Propensity Score Matching Analysis.

Is the Hong Kong Liver Cancer Staging System the Best Guide for Hepatitis B Virus-Related Hepatocellular Carcinoma Patients with Multiple Tumors?

Editorial: Interventional Therapy of Hepatocellular Carcinoma

Liver Resection Criteria for Patients with Hepatocellular Carcinoma and Multiple Tumors Based on Total Tumor Volume

Preoperative transcatheter arterial chemoembolization for resectable large hepatocellular carcinoma: A reappraisal

Effect of resection following downstaging of unresectable hepatocelluar carcinoma by transcatheter arterial chemoembolization

The role of adjuvant transcatheter arterial chemoembolization following repeated curative resection/ablation for hepatocellular carcinoma with early recurrence: a propensity score matching analysis

Comparison Between Chemoembolization Combined with Radiotherapy and Chemoembolization Alone for Large Hepatocellular Carcinoma

Exploratory Study of Microparticle Transcatheter Arterial Chemoembolization Combined with Resection for Huge Hepatocellular Carcinoma

Experience with Liver Resection after Hepatic Arterial Chemoembolization for Hepatocellular Carcinoma.

Efficacy of Hepatic Resectionvstransarterial Chemoembolization for Solitary Huge Hepatocellular Carcinoma

Systematic Review of Single Large and/or Multinodular Hepatocellular Carcinoma: Surgical Resection Improves Survival.

Combined treatment for the postoperative recurrence of hepatocellular carcinoma

The Combination Strategy of Transarterial Chemoembolization and Radiofrequency Ablation or Microwave Ablation Against Hepatocellular Carcinoma

Comparison of surgical resection and transcatheter arterial chemoembolization for large hepatocellular carcinoma: a systematic review and meta-analysis

Preoperative transcatheter arterial chemoembolization and prognosis of patients with solitary large hepatocellular carcinomas (≥5 cm): Multicenter retrospective study

Transcatheter Arterial Chemoembolization Combined with Hepatic Arterial Infusion Chemotherapy Versus Transcatheter Arterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Systematic Review and Meta-analysis

Improved survival with resection after transcatheter arterial chemoembolization (TACE) for unresectable hepatocellular carcinoma

Three Decades' Experience In Surgery Of Hepatocellular Carcinoma